MEDICAL TRADEMARKS
Trademark registration system
Trademarks in Mexico are regulated under the Industrial Property Law (IPL) and its regulations. In general, businesses, merchants, or service providers can use trademarks in industry, commerce or in the services they render (Article 87, IPL). Te right to their exclusive use is obtained through their registration with the Mexican Institute of Industrial Property (IMPI). Any person or entity is entitled to apply for a trademark registration before the IMPI, and actual use is not required by the IPL.
All visible signs can be protected provided that they are sufficiently distinctive, and are able to identify the products or services to which they are applied, or are intended to be applied, from those in the same class (Article 89, IPL). Under this definition, olfactory and auditory trademarks cannot be protected. However, three-dimensional signs can be protected as trademarks since these are visible signs. What cannot be protected as a trademark is set out in a rather long article (Article 90, IPL), which contains a list of general prohibitions and the only legal grounds for rejecting a trademark application.
In addition to the general, absolute and relative prohibitions provided in the IPL, in the case of brands related to medicinal products, Mexican trademark examiners have a special rule regarding registrability based on the Mexican Health Law (MHL): if a junior trademark application does not have at least a three-letter difference from a senior trademark registration, and is confusingly similar, the junior one will not be registered. Even though the MHL is not binding for trademark matters as it is not included in the IPL, Mexican examiners use their discretion to apply it.
As well as this special criterion, when applying for a trademark registration, applicants must bear in mind that medicinal products fall into class 5, which includes many other types of goods that are unrelated, such as baby foods, disinfectants, fungicides and herbicides.
Tis should not be a problem as long as a junior trademark application is refused only if it is confusingly similar to a senior trademark registration and the goods sought to be protected are the same as, or related to, ones covered by the older trademark registration.
However, as mentioned above, actual use of a trademark in the Mexican market is not a
www.worldipreview.com
“HAVING A TRADEMARK REGISTRATION FOR THE DISTINCTIVE NAME WILL NOT MAKE ANY DIFFERENCE FOR THE PURPOSES OF GETTING A MARKETING AUTHORISATION WITH THAT TRADEMARK.”
Te basic set of rules regarding the pharmaceutical or drug names is as follows:
as the name or trademark assigned by the laboratory or manufacturer to its pharmaceutical products, in order to distinguish it from other similar products, and prior approval of health
authority and registration with
the the
competent authorities is required (Section IV, Article 2 MHL Regulations);
identified by their distinctive and generic names. Generic identification is required (Article 225 MHL);
unclear, reference to the composition of the medicinal product or its therapeutic action. No indications
are permitted in relation
requirement to apply for, or get, trademark protection, so in domestic practice any applicant may request the broadest protection possible— that is, all the products that are covered in a single class.
Terefore, when choosing a trademark in Mexico for a medicinal product, the applicant needs to make a careful and deep search, bearing in mind all the peculiarities of the Mexican system, to evaluate the possibilities of achieving trademark rights.
Obtaining a trademark registration does not, however, automatically mean that trademark owner is able actually to use the trademark on medicinal products. Tere is yet another process that involves a different authority, and has its own characteristics.
Health authorisation process
According to our legal system, the process to obtain marketing authorisation from the Federal Commission for Protection against Sanitary Risks (COFEPRIS) of
the Mexican Health
Authority for a medicinal product includes a review and approval for the pharmaceutical or drug name, referred to by our regulatory bodies as a ‘distinctive name’. Failure to propose an acceptable name will result in a bar to obtaining marketing authorisation.
Te specific requirements and rules regarding distinctive names are provided under the MHL and its regulations.
to diseases, syndromes, symptoms, nor anatomical data or physiological phenomena, except for vaccines and biological products (Article 225 MHL);
when it is confusingly similar to a prior authorised drug name, in which case the difference between the proposed and the prior drug name should be at least three letters in each word (Article 23 MHL Regulations);
proposal is identical to a prior distinctive name of another drug with existing health registration (Article 23 MHL Regulations); and
only in the case of different pharmaceutical forms or different doses with the same principal active
ingredient and registered
by the same laboratory (Article 23 MHL Regulations).
Although a legal definition of a distinctive name is provided under Section IV, Article 2 of the MHL Regulations—including that it is subject to the approval of the corresponding authorities— in practice, prior approval and registration with other relevant agencies, such as IMPI, is not required for the application and granting of the distinctive name before COFEPRIS. In fact, having a trademark registration for the distinctive name will not make any difference for the purposes of getting a marketing authorisation with that trademark.
Life Sciences Intellectual Property Review 2012 53
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64